anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study is to investigate the therapeutical effect and mechanisms of human-derived adipose mesenchymal stem cells (ADSC) in relieving adriamycin (ADR)-induced nephropathy (AN). SD rats were separated into normal group, ADR group, ADR+Losartan group (20 mg/kg), and ADR + ADSC group. AN rats were induced by intravenous injection with adriamycin (8 mg/kg), and 4 d later, ADSC (2 × 105 cells/mouse) were administrated twice with 2 weeks interval time (i.v.). The rats were euthanized after the 6 weeks' treatment. Biochemical indicators reflecting renal injury, such as blood urea nitrogen (BUN), neutrophil gelatinase alpha (NGAL), serum creatinine (Scr), inflammation, oxidative stress, and pro-fibrosis molecules, were evaluated. Results demonstrated that we obtained high qualified ADSCs for treatment determined by flow cytometry, and ADSCs treatment significantly ameliorated renal injuries in DN rats by decreasing BUN, Scr and NGAL in peripheral blood, as well as renal histopathological injuries, especially protecting the integrity of podocytes by immunofluorescence. Furthermore, ADSCs treatment also remarkably reduced the renal inflammation, oxidative stress, and fibrosis in DN rats. Preliminary mechanism study suggested that the ADSCs treatment significantly increased renal neovascularization via enhancing proangiogenic VEGF production. Pharmacodynamics study using in vivo imaging confirmed that ADSCs via intravenous injection could accumulate into the kidneys and be alive at least 2 weeks. In a conclusion, ADSC can significantly alleviate ADR-induced nephropathy, and mainly through reducing oxidative stress, inflammation and fibrosis, as well as enhancing VEGF production.
The barbiturates are nonselective central nervous system (CNS) depressants that are primarily used as sedative-hypnotics. In subhypnotic doses, they are also used as anticonvulsants. The barbiturates and their sodium salts are subject to control under the Federal Controlled Substances Act.

Phenobarbital is a barbituric acid derivative and occurs as white, odorless, small crystals or crystalline powder that is very slightly soluble in water; soluble in alcohol, in ether, and in solutions of fixed alkali hydroxides and carbonates; sparingly soluble in chloroform. Phenobarbital is 5-ethyl-5-phenylbarbituric acid. Phenobarbital is a substituted pyrimidine derivative in which the basic structure is barbituric acid, a substance that has no CNS activity. CNS activity is obtained by substituting alkyl, alkenyl, or aryl groups on the pyrimidine ring. It has the following structural formula:

Each phenobarbital tablet contains 16.2 mg (1/4 gr), 32.4 mg (1/2 gr), 64.8 mg (1 gr) or 97.2 mg (11/2 gr) of phenobarbital.

In addition each tablet contains: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, microcrystalline cellulose and sodium starch glycolate.
Method and apparatus for configuring computer tasks which construct data objects. The system user is able to configure these tasks by the simple expedient of clicking on a toggle switch displayed on a user interface screen or menu. In response to operation of the toggle switch, a selected one of a pair of attribute control files associated with the particular task will be utilized during object construction. The menu contains a list of the activated configured remote devices for the particular imaging system. Next to each device name is a virtual toggle switch (defaulted to OFF). In the OFF state, the task will be configured in accordance with the first attribute control file which is compliant with a first communications standard. If the user toggles the switch for a particular device to ON (this can be done on a per device basis), then the task will be configured in accordance with the second attribute control file which is compliant with a second communications standard. By toggling switches on the menu, the user is able to tell the system which attribute control file to use (to configure a task) for which remote device.
The safety and efficacy of F-18 FDOPA were evaluated in a prospective single-arm study conducted at a single center that enrolled 68 adult patients with possible Parkinsonian syndrome (PS). In the study, F-18 FDOPA image reads were compared to a reference clinical diagnostic standard of Parkinsonian syndrome or non-Parkinsonian syndrome (non-PS) established at 6 to 9 months after the F-18 FDOPA PET scan by a movement disorder specialist blinded to F-18 FDOPA PET results. The reference clinical diagnostic standard for PS included Parkinson's disease (PD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). These conditions have been associated with dopaminergic neurodegeneration and F-18 FDOPA PET imaging was not designed to distinguish among the conditions. The reference clinical diagnostic standard for non-PS included essential tremor (ET) diagnosis, vascular parkinsonism, drug-induced parkinsonism, and other non-PS diagnoses.

Carbidopa (150 mg) was administered orally to patients approximately 60 minutes prior to the administration of Fluorodopa F 18 Injection. Each patient was injected 5 mCi F-18 FDOPA (range 4.5-5.5 mCi), and PET images were acquired 80-100 minutes post injection.

F-18 FDOPA PET images were evaluated independently by 3 readers blinded to clinical information who had no other role in patient assessment. Patients with at least one cardinal feature of PS were referred to the study by physicians who were uncertain of a diagnosis. Thirty-three of these patients had symptoms for 2 years or less. Fifty-six of these patients completed F-18 FDOPA PET imaging and at least 6 month clinical follow-up. Among these 56 patients, 32% were female and 68% were male. Mean patient age was 66 years. Thirty-three patients were categorized as PS, and twenty-three patients were categorized as non-PS based on minimum 6 month clinical follow-up by a movement disorder specialist.

Table 5 shows the positive percent agreement and negative percent agreement of F-18 FDOPA Injection PET image results with the reference clinical diagnostic standard. Positive percent agreement represents the percent of patients with positive F-18 FDOPA PET images among all the patients with a clinical diagnostic reference standard of PS. Negative percent agreement represents the percent of patients with negative F-18 FDOPA PET images among the patients with a non-PS clinical diagnostic reference standard.

The effectiveness of F-18 FDOPA PET as a screening or confirmatory test and for monitoring disease progression or response to therapy has not been established.
Various types of synbiotic therapies are provided for the treatment of a variety of gastrointestinal and other disorders. The combination of prebiotics to probiotics is defined as a synbiotic therapy. The principal GI disorders associated with dysbiosis that can be treated from such a therapeutic intervention include but are not limited to: inflammatory bowel disease (IBD) (Crohn's disease and ulcerative colitis), irritable bowel syndrome (IBS), antibiotic-associated diarrheas such as recurrent  Clostridium difficile  infection, and possibly variants of Celiac disease. Other disorders that may also be ameliorated by the proposed synbiotic therapy include metabolic syndromes and central nervous system disorders. The disclosed methods and compositions were developed to improve upon currently available probiotics through consideration of the human intestinal microbiota, and its relationship to various intestinal metabolic and neuropsychiatric disorders. In one embodiment, the disclosed synbiotic compositions include prebiotics and a targeted delivery system, which altogether promote the survival, growth, and attachment of probiotic microbiota.
PCT No. PCT/FR88/00296 Sec. 371 Date Dec. 11, 1989 Sec. 102(e) Date Dec. 11, 1989 PCT Filed Jun. 10, 1988 PCT Pub. No. WO88/09654 PCT Pub. Date Dec. 15, 1988.A composition comprising hydrated lipidic lamellar phases of liposomes containing a mulberry component. The composition may also contain kojic acid or its salts or esters, hydroquinone, or a mixture of kojic acid or its salts or esters and hydroquinone. This composition has skin-lightening properties or anti-inflammatory activity and has pharmaceutical and cosmetic applications. A method for lightening the skin or for applying anti-inflammatory formulation to the skin by applying to the skin a composition comprising hydrated lipidic lamellar phases or liposomes containing a mulberry component.
There are over five million Americans living with heart failure (HF), and another 670,000 new cases being diagnosed each year. HF is a characteristically unstable condition that is the most costly diagnosis in the Medicare population and is the most common cause for hospitalization. The instability of HF disease is reflected in short-term fluctuations of the HF disease biomarker, B-Type Natriuretic Peptide (BNP). Patient self-management behaviors are important for minimizing HF disease instability. Depression is often comorbid with HF, and elevated depressive symptoms are associated with a marked increase in adverse clinical outcomes. For both depressed and non-depressed HF patients, worsening depressive symptoms mark a substantially increased risk of cardiovascular hospitalization or death. Despite the risk associated with depressive symptoms, the nature of their association with a worsening HF disease trajectory and adverse clinical outcomes is poorly understood.

Converging evidence suggests that the association between depressive symptoms and accelerated HF disease progression may involve multiple behavioral and pathophysiological pathways. This study proposes an innovative, prospective bio-behavioral monitoring study of 220 HF patients that is designed to address the issue of how depressive symptoms and their bio-behavioral manifestations are implicated in worsening HF disease. Using home-monitoring biotechnology, we propose to track fluctuations in HF disease severity using biweekly assessments of BNP over a 16-week period. Symptoms of depression and HF-related health behaviors also will be assessed biweekly via concurrent monitoring. This biweekly bio-behavioral monitoring will be framed by comprehensive baseline and 4-month assessments of depression, HF disease severity, and pathophysiological mechanisms that have been related to the presence of depressive symptoms and implicated in the progression of HF disease. Clinical outcomes also will be assessed over a 5 year follow-up period. This study will create a unique data structure that will allow us to use contemporary statistical methods that will serve to elucidate causal associations between depressive symptoms, self-management health behaviors, pathophysiological processes, and HF disease progression and clinical outcomes. The study findings are expected to yield important advances in our understanding of why depressive symptoms may be particularly detrimental in the presence of HF and will help to inform the design of future clinical trials.
1. Method of carrying out cell transfection and achieving bio-accessibility of genetic material in vitro and ex vivo - Characterized in that: The cells to be transfected are contacted with a dendritic polymer complex containing genetic material, where the ratio of the genetic material to the dendrimer is within the range between about 1:1 and about 1:100, while the process is carried out in the solution of DEAE-dextran or glycerine. The dendritic polymer constitutes at least one solvent-soluble radially-symmetrical dendrimer, which contains at least one branch leaving from the core and containing at least one final group, while (1) the ratio of final groups to core branches is equal to two or more; (2) the density of final groups per polymer volume unit is at least 1.5 times larger than the density of a conventional elongated star-shaped polymer with a similar core and monomer components, with a comparable molecular weight and number of branches, while each branch of the elongated conventional star-shaped polymer contains only one final group; and (3) the molecule volume, determined on the basis of dimension examination by means of scalable molecule models of Corey-Pauling, constitutes not more than about 80 percent of the volume of the elongated conventional star-shaped polymer, and the polymer contains regular dendritic branches. 3. The method of carrying out cell transfection and achieving bio-accessibility of genetic material in vitro and ex vivo - Characterized in that: A complex of genetic material with the first dendritic polymer is produced. The dendritic polymer constitutes at least one solvent-soluble radially-symmetrical dendrimer, which contains at least one branch leaving from the core and containing at least one final group, while (1) the ratio of final groups to core branches is equal to two or more; (2) the density of final groups per polymer volume unit is at least 1.5 times larger than the density of a conventional elongated star-shaped polymer with a similar core and monomer components, with a comparable molecular weight and number of branches, while each branch of the elongated conventional star-shaped polymer contains only one final group; and (3) the molecule volume, determined on the basis of dimension examination by means of scalable molecule models of Corey-Pauling, constitutes not more than about 80 percent of the volume of the elongated conventional star-shaped polymer, and the polymer contains regular dendritic branches. Then, the complex is placed in a solution containing the second dendritic polymer, as defined above, but with larger molecules than in the case of the first dendritic polymer. The obtained complex and the second dendritic polymer are contacted with the cells to be transfected.
Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a "double dummy" design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally \>8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose.
All participants underwent otoscopy and tympanometry, responded to the Profile of Mood State (POMS), submitted to the cVEMP, oVEMP and caloric tests in that order. After that they received caffeine capsule (300mg). After 45 minutes they again responded to the POMS, repeated the cVEMP, oVEMP and caloric test.
The present invention belongs to an improvement of formula materials of medical care sanitary accessories for women, particularly to a medical sanitary tampon for women and a preparation method. The medical sanitary tampon for women is prepared by mixing antibacterial powder in nano-silver class with substrates for tampons. The preparation method has the steps: heating substrates for tampons to melt the substrates; adding the antibacterial powder in nano-silver class into the melted substrates; oscillating the mixture by ultrasonic waves to thoroughly disperse the antibacterial powder in nano-silver class at the temperature of keeping melting; injecting the final mixture into a general mould for preparing a sanitary tampon; cooling and coagulating the final mixture to obtain the sanitary tampon. The present invention has the functions of resisting bacteria, relieving inflammation and treating vaginitis of women, and solves the problem that medicine tampons have side effects and medicine tolerance. Compared with tampons sold on the markets at present, the present invention has obvious therapeutic effects on gynecological cervicitis and various kinds of vaginitis and sexual diseases. The present invention also solves the problem that medicine tampons only aim at certain pathogenic bacteria or several kinds of bacteria, and thus, has wide range of application and broad market prospects.
PROBLEM TO BE SOLVED: To obtain a cosmetic composition improved in the binding of a ceramide to hair fibers or their interior or skin or its interior by adding a specific peptide into a stable aqueous disperion system consisting essentially of a ceramide type lipid compound. SOLUTION: This cosmetic composition is obtained by combining a ceramide type lipid compound with at least one peptide having at least one fatty chain in a cosmetically acceptable aqueous medium. A compound represented by the formula (R1 is a 9-30C hydrocarbon, etc.; R2 is H, a hydrocarbon or a 15-26C α-hydroxylalkyl; R3 is H, a 16-27C hydrocarbon, etc.; R4 is H or a mono- or a polyhydroxylated 1-4C hydrocarbon) is especially preferred as the ceramid compound. For example, the compound is N-linoleoyldihydrosphingosine. A protein having a fatty chain or a protein hydrolyzate is preferred as the peptide. The ceramide type lipid compound is preferably formulated in an amount of 0.0001-5 wt.% and the peptide is preferably formulated in an amount of 0.01-30 wt.%.
The objective was to compare the symptom networks of long-COVID and chronic fatigue syndrome (CFS) in conjunction with other theoretically relevant diagnoses in order to provide insight into the etiology of medically unexplained symptoms (MUS). This was a cross-sectional comparison of questionnaire items between six groups identified by clinical diagnosis. All participants completed a 65-item psychological and somatic symptom questionnaire (GSQ065). Diagnostically labelled groups were long-COVID (N = 107), CFS (N = 254), irritable bowel syndrome (IBS, N = 369), fibromyalgia (N = 1,127), severe asthma (N = 100) and healthy group (N = 207). The 22 symptoms that best discriminated between the six groups were selected for network analysis. Connectivity, fragmentation and number of symptom clusters (statistically related symptoms) were assessed. Compared to long-COVID, the symptom networks of CFS, IBS and fibromyalgia had significantly lower connectivity, greater fragmentation and more symptom clusters. The number of clusters varied between 9 for CFS and 3 for severe asthma, and the content of clusters varied across all groups. Of the 33 symptom clusters identified over the six groups 30 clusters were unique. Although the symptom networks of long-COVID and CFS differ, the variation of cluster content across the six groups is inconsistent with a modular causal structure but consistent with a connectionist (network, parallel distributed processing) biological basis of MUS. A connectionist structure would explain why symptoms overlap and merge between different functional somatic syndromes, the failure to discover a biological diagnostic test and how psychological and behavioral interventions are therapeutic.
As a constituent of the Per- and Polyfluoroalkyl Substances (PFAS) family, perfluorodecanoic acid (PFDA) is ubiquitous in the environment and enters the human body through environmental exposure, the food chain, and other pathways, resulting in various toxic effects. Previous population-based studies have suggested a correlation between PFDA exposure and inflammation. However, the evidence is still limited, and the potential mechanisms underlying this correlation remain to be further elucidated. In our study, we observed that exposure to internal doses of PFDA significantly promoted macrophage inflammation through in vitro assays. Utilizing RNA-seq screening and molecular experiments, we identified that environmentally relevant concentration of PFDA promote inflammation mainly by activating non-canonical cGAS/STING/NF-κB pathways in vitro. Finally, we confirmed in the typical mouse inflammatory bowel disease (IBD) model that PFDA could exacerbate intestinal inflammation in a cGAS dependent manner. In conclusion, our research firstly demonstrated that even at environmentally relevant concentrations, PFDA could promote the progression of intestinal inflammation primarily through the cGAS/STING/NF-κB pathway, revealing the potential risk associated with PFDA exposure and providing theoretical evidence for its management.
The incidence of early-onset cancers in adolescents and young adults (AYA) has been increasing worldwide since the 1990s. In Italy, a significant increased rate of 1.6 % per year has been reported for early-onset cancers among females between 2008 and 2016. This is mainly attributable to melanoma, thyroid, breast and endometrial cancer. The aim of our work was to describe temporal trends of the main established lifestyle risk factors (tobacco use, alcohol consumption, obesity, physical inactivity, dietary westernization and reproductive factors) over the last 20 years in the Italian AYA population. Available data on behavioural risk factors, individual and household daily life have been obtained and elaborated from PASSI, ISTAT and Eurostat reports. Lowering age of smoking initiation, an increase in alcohol drinkers among young females, and an obesity and overweight epidemic, particularly among children and adolescents as a result of physical inactivity and dietary habits, may be contributing factors behind this cancer epidemic, especially among females. In-depth investigations are needed to understand the exact role of each contributing factor, the effects of exposure to nicotine-containing products and environmental factors such as endocrine disruptors that could play a role in this phenomenon.
The magnitude of muscle hypertrophy in response to resistance training (RT) is highly variable between individuals (response heterogeneity). Manipulations in RT variables may modulate RT-related response heterogeneity; yet, this remains to be determined. Using a within-subject unilateral design, we aimed to investigate the effects of RT volume manipulation on whole muscle hypertrophy [quadriceps muscle cross-sectional area (qCSA)] among nonresponders and responders to a low RT dose (single-set). We also investigated the effects of RT volume manipulation on muscle strength in these responsiveness groups. Eighty-five older individuals [41M/44F, age = 68 ± 4 yr; body mass index (BMI) = 26.4 ± 3.7 kg/m2] had one leg randomly allocated to a single (1)-set and the contralateral leg allocated to four sets of unilateral knee-extension RT at 8-15 repetition maximum (RM) for 10-wk 2 days/wk. Pre- and postintervention, participants underwent magnetic resonance imaging (MRI) and unilateral knee-extension 1-RM strength testing. MRI typical error (2× TE = 3.27%) was used to classify individuals according to responsiveness patterns. n = 51 were classified as nonresponders (≤2× TE) and n = 34 as responders (>2× TE) based on pre- to postintervention change qCSA following the single-set RT protocol. Nonresponders to single-set training showed a dose response, with significant time × set interactions for qCSA and 1-RM strength, indicating greater gains in response to the higher volume prescription (time × set: P < 0.05 for both outcomes). Responders improved qCSA (time: P < 0.001), with a tendency toward higher benefit from the four sets RT protocol (time × set: P = 0.08); on the other hand, 1-RM increased similarly irrespectively of RT volume prescription (time × set: P > 0.05). Our findings support the use of higher RT volume to mitigate nonresponsiveness among older adults.NEW & NOTEWORTHY Using a within-subject unilateral design, we demonstrated that increasing resistance training (RT) volume may be a simple, effective strategy to improve muscle hypertrophy and strength gains among older adults who do not respond to low-volume RT. In addition, it could most likely be used to further improve hypertrophic outcomes in responders.